Results: TS, EGFR and VEGF were an independent prognostic factor for time to progression (TTP) and overall survival (OS). Findings of at least two maximum expressed investigated markers, significantly increases the risk of progression which influences shorter five year survival, and the single maximum expression does not necessarily have to be a bad prognostic sign.
INTRODUCTION
C olorectal cancer (CRC) is the second most common cause of cancer death in Western world, responsible for almost 500 000 deaths each year. Every year, more than 1 000 000 patients are diagnosed in the world with CRC. Of these patients, 40% will present with stage III disease, with nodal spread but not visible distant metastases 1 . There is clear evidence that offering adjuvant therapy significantly improved survival in stage III CRC. But, despite radical surgery and adjuvant therapy, more than half of CRC patients develop metastases 2 
.
Newer and more efficacious agents in adjuvant or metastatic setting, over the last ten years, enable improvement in median overall survival. Unfortunately, the success is still far from perfect considering tumor response which is still around 50%. Adding expense of toxicities, we must admit that only palliative effect is possible, especially in metastatic setting 3 . Further more, management of stage II CRC is in special area of controversy and debate. The 5-year survival for stage II patients is approximately 75%, indicating that majority of patients are cured by surgery alone but some who are not recommended to receive adjuvant therapy still may benefit from chemotherapy(4). That's why we are more and more interested in studies which started to define prognostic markers that identify those patients at risk of relapse after surgery and who may benefit from chemotherapy. Prognostic biomarkers may be useful for identifying high-risk patients with resected, node-negative/positive disease, and this stratification may represent an innovative strategy for designing adjuvant chemotherapy trials. Plus, seems that some molecular markers can predict whether a tumor will respond to a particular chemotherapy. The ultimate goal of this researchs is the tailoring of treatment to the molecular phenotypes of tumor and patient 4 . In our study we examined the possible prognostic relevance of intratumoral levels of thymidilate synthase (TS), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in 100 stage III CC patients during five years follow up period from primary operation.
Thymidilate synthase (TS)
TS may be a factor which can forecast prognosis in primary and metastatic disease of CRC. This enzyme is involved in the biosynthesis of DNA and is considered to be the main intracellular target of 5 FU. There are now a numerous clinical studies demonstrating that the level of intratumoral TS in primary CRC may be of prognostic im- . TS quantification can be performed by immunohistochemistry or RNA levels, and high TS levels have been correlated with poor response rates to fluorouracil-based chemotherapy in advanced gastrointestinal carcinomas 6 . In colorectal cancer, fluorouracil-based chemotherapy is widely used as post-surgical adjuvant treatment, and the prognostic role of TS quantization has been investigated in patients with early and advanced disease 7, [8] [9] [10] [11] [12] [13] [14] [15] [16] . Since the first report in 1994. by Johnston et al. 5 , who found a significant association between TS levels and survival in 294 patients with rectal cancer, further studies have addressed the prognostic role of TS in colorectal cancer patients. In the majority of these studies TS quantization was found to be an independent prognostic factor of postoperative outcome; in particular, patients with TSpositive tumors showed poorer survival than patients with TS-negative tumors [8] [9] [10] [11] [12] [13] [14] [15] [16] . But, Allegra et al. 7 failed to demonstrate a consistent and significant association between TS quantification and either disease-free survival or overall survival. In this study, the prognostic role of TS was evaluated according to different TS scores that were based on staining intensity and staining patterns. Edler et al. 14 found that TS expression was an independent prognostic factor in the whole group of 862 patients and in the 442 Dukes' B patients who underwent surgery alone. On the contrary, in 420 patients treated with fluorouracil-based adjuvant chemotherapy, TS quantization lost its prognostic value and patients with low TS levels showed even worse outcome than patients treated with surgery alone.
Vascular endothelial growth factor (VEGF)
Angiogenesis plays a key role in tumor growth and metastasis. This phenomenon may have prognostic relevance and it can be assessed by the analysis of angiogenesis promoting molecules. VEGF is a glycoprotein similar to platelet-derived growth factor, and it is considered to be the main angiogenic stimulator 17 . VEGF expression can be determined by the analysis of mRNA levels or by immunohistochemistry with anti-VEGF antibodies, in fresh or paraffin-embedded tumor tissues 18 . The prognostic role of angiogenesis features in early stage colorectal cancer has been investigated in retrospective series of patients 19, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Seven studies 19, [20] [21] [22] [23] [24] 26 showed the prognostic analysis in stage Dukes' B patients, and in this group, three investigations found an independent prognostic role of vascular count 19, 21, 22 and one investigation with VEGF found worse disease-free survival in Dukes' B patients whose tumors showed expression in 10% of tumor cells 26 . Preclinical studies have shown that a murine antihuman monoclonal antibody against VEGF can inhibit the growth of human tumor xenografts 36 , and a humanized variant of this antibody (bevacizumab "Avastin") 37 is being evaluated in clinical trials as a treatment for various cancers. From clinical practice, Hurwitz at all 38 published the data were found that the addition of bevacizumab to IFL significantly improved overall survival. Furthermore, the increase of 4.7 months in the median duration of survival attributable to bevacizumab is as large as or larger than that observed in any other phase 3 trials for the treatment of colorectal cancer
39
. The median survival of 20.3 months in the bevacizumab-treated population occurred in spite of the limited availability of oxaliplatin for second-line therapy during this trial. So, the addition of bevacizumab to bolus IFL conferred a clinically meaningful and statistically significant improvement in overall survival, progression-free survival, and response rate. These results suggest that bevacizumab plus fluorouracil-based chemotherapy should be considered a new option for the treatment of metastatic colorectal cancer.
Results of TREE-2 study showed that combination of bevacizumab and oxaliplatin (Ox) as well improved response and survival in CRC patients. This randomized, multicenter trial was designed to assess the safety, tolerability and efficacy of each of three oxaliplatin plus bolus (b), infusional or oral fluoropyrimidine (FP) regimens 
Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor (EGFR) is another transmembrane protein with tyrosine kinase activity. The frequency of EGFR over expression in colorectal carcinomas seems to be higher than that reported for the HER-2 glycoprotein 41 , and EGFR inhibitors are under investigation in clinical trials for the treatment of colorectal cancer.
Earlier studies have shown that increased expression of EFGR in tumors of head and neck, ovarian, bladder, esophagus and colon is directly related to a bad prognosis in such patients [42] [43] [44] [45] . This is especially the case in studies where it is also confirmed the increased expression of growth factor (EGF, TGF-a) and that these factors influence the faster transformation into malignant cells. However, some studies have not proved the prognostic significance of expression of this receptor in patients with colon cancer 46 . Because the present therapy has not proven very effective, especially in metastatic disease of colon cancer, along with chemotherapy it is necessary to introduce additional targeted therapy aimed at blocking EGFR activity with patients who expressed increased EGFR either by monoclonal antibodies or by deploying small moleculeblockers of intracellular part of this receptor.
The successes of these studies have proven that interruption of transduction signals can have good therapeutically effect with these patients [47] [48] [49] . The main difference between classical chemotherapy (5FU, irinotecan, oxaliplatin) and new medications (antibodies to EGFR and VEGF) is that the former acts directly and (relatively) nonselective to RNA or DNA, and the later, interrupts the process of consecutive signal transduction within the malignant cells, thus attempting to influence the pathways of cellular differentiation, proliferation, apoptosis and survival 50 . Cetuximab (Erbitux) is a chimeric IgG1 monoclonal antibody that binds to EGFR with high specificity and with a higher affinity than either epidermal growth factor or TGF-, thus blocking ligand-induced phosphorylation of EGFR. In addition, cetuximab enhances the effects of irinotecan 51 and radiotherapy in experimental systems. Results of BOND study by Cunningham at all showed that the rate of response in the combination-therapy group (Irinotecan Cetuximab) was significantly higher than that in the monotherapy group (22.9 % vs. 10.8 %, p=0.007). The median time to progression was significantly greater in the combination-therapy group (4.1 vs. 1.5 months, P by the log-rank test). The median survival time was 8.6 months in the combination-therapy group and 6.9 months in the monotherapy group (P=0.48). Toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone. In summary, Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer 52 .
PATIENTS AND METHODS
In our study total of 100 (hundred) patients we entered following primary operation of colon cancer (rectal cancer patients were excluded). All patients were stage III and were operated in our hospital between January 1997. and 2002. After operation all received the same adjuvant chemotherapy with 5FU/Leucovorin according to Mayo protocol. Follow up period was five years after primary operation. Considering the clinical course we classified patients in two groups: "good" and "bad" with 50 patients in each group. In "good" group neither of patients progressed during the follow up period and all were alive at the end of study. In "bad" group all patients progressed during follow up period.
We designed the investigation described here to assess the value of TS, EGFR and VEGF expression as potential prognostic markers in patients with Dukes C colon cancer. 
IMMUNOHISTOCHEMISTRY METHODS
Tissue blocks collected from patients were stored and processed at the Department of Pathology of Military Medical Academy. The standard avidin-biotin-peroxidase complex technique was used. After adequate preparatation of each specimen slides were deparaffinized, rehydrated and incubated with antibodies. We used primary monoclonal antibodies in optimal or comercial concentrations (LSAB DAKO prediluted) :
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RESULTS

Expression of tumor markers
Markers were classified in the two categories considering tissue scoring: low (0, 1 and 2) and high (3).
In the group with the bad prognosis (B) there were 21 patients (42%) with high expression of TS while in the group with good prognosis (G) were only 7 patients (14%) with the high expression of TS expression. This difference was statistically significant (Fisher Exact Test, p< 0,002). (Fig 1.) In the group with the bad prognosis (B) there were 34 patients (68%) with high expression of EGFR while in the group with good prognosis (G) were only 6 patients (12%) with the highest expression of EGFR. This difference was again statistically significant (Fisher Exact Test, p< 0,001). (Fig 2.) In the group with the bad prognosis (B) there were 32 patients (64%) with high expression of VEGF while in the group with good prognosis (G) were only 7 patients (14%) with high expression of VEGF. This difference was statistically significant (Fisher Exact Test, p<0,001). (Fig  3.) Considering that it is noted that the maximum values of expression of all examined molecular markers were more frequent in the group with the bad prognosis we made an additional assessment by examining the frequency of occurrence of the highest values. In respect with the groups of examined patients, in the group with the good prognosis there were 30 patients (60%) who did not have any maximum expressed parameters and 20 patients (40%) who had only one maximum expressed parameter. There were no patients in the group with good prognosis who had two or three maximum expressed parameters.
In the group with bad prognosis the situation was quite the opposite. There were only 5 patients (10%) with no maximum expressed parameters with three of which are still alive. With one parameter there were 13 patients (26%), and 32 patients (64%) had at least two maximum expressed parameters. With two parameters were 22 patients (44%) and 10 patients (20%) had all three maximum expressed parameter, with nine of which died in first two years of follow up.
Such high expression of maximum values of followed parameters, in regard to groups of patients shows significant difference in its distribution. In the group with bad clinical prognosis there were all patients with two maximum expressed markers and with all three maximum expressed parameters. In the group with good prognosis there were no such patients who show very high statistical significance (Fisher Exact Test; p<0,001). (Fig 4.) 
Time to progression and overall survival
The median time to progression (TTP) in the group with maximum expression TS was 12 months with 95% CI (confidence interval) 6, 19 . In this group 75% of patients progressed and 25% did not.
In the group with the lower expression TS the median was not reached +hwith 95% CI /24 +h/, or 60% of patients with low expression TS did not progress. The difference in TTP between the groups was statistically significant (Long -Rank test; p=0,001). (Fig 5. The median time of survival (OS) in the group with the maximum expression of TS was 36 months with 95% /CI 29+h/. In this group 39% of patients were alive after five years and 61% of patients died within five years from operation.
In the group with lower expression TS, the median was not reached which indicates that 68% of patients were alive after five years from operation. The comparison of time difference in OS between the groups with high and low expression TS showed significant statistical result (Long -Rank test; p=0,009). (Fig 6.) The median TTP in the group with maximum expression EGFR was 12 months with 95% CI /6,17/. In this group total of 85% of patients progressed as opposed to 15% who did not.
In the group with the lower expression EGFR the median TTP was not reached, which means that 73% of patients with lower expression EGFR did not progress. The difference in TTP between the groups with maximum and lower expression EGFR was very statistically significant (Long -Rank test; p< 0,001). (Fig 7.) The median time of OS in the group with the maximum expression EGFR was 30 months with 95% /CI 29+h/, so 68% of patients died within five years from operation. In the group with the lower expression EGFR the median OS was not reached, which means that 78% of patients were alive five years after operation. The difference in OS between the groups with maximum and lower expression of EGFR was very statistically significant (Long -Rank test; p< 0,001). (Fig 8.) The median TTP in the group with maximum expression VEGF was 11 months with 95% CI /6,16/. In this group total of 82% patients progressed as opposed to 18% who did not.
In the group with the lower expression VEGF the median TTP was not reached, and where 70% of patients with lower expression VEGF did not progress. The difference in TTP between the groups with maximum and lower expression VEGF was very statistically significant (Long -Rank test; p< 0,001). (Fig 9.) The median time of OS in the group with the maximum expression of VEGF was 30 months with 95% CI /29,36/, having 77% of patients who died within five years from operation.
In the group with the lower expression VEGF the median OS was not reached, and where 83% of patients were alive five years after operation The comparison of time difference in survival between the groups with high and low expression VEGF shows very high statistical significance (Long -Rank test; p< 0,001). (Fig 10.) 
DISCUSSION
There is an increasing need to defining new factors that may be used to forecast prognosis in colorectal cancer and its response. Measurements of TS, EGFR and VEGF have been shown to be of interest because of the possible role of these enzymes in the clinical course of this disease.
It was proven in previous studies that patients with high intratumoral expression of these three markers had a poorer clinical course.
We have shown in our study that patients with maximum TS expression represent the high risk patients with high probability of developing progression of the disease with consequently shorter survival.
It is particularly interesting that this study showed that in case of multiple highest expressions of these investigated markers, findings of at least two maximum expressed markers, significantly increases the risk of progression which influences shorter five year survival, and that the single maximum expression does not necessarily have to be a bad prognostic sign. (Fig 11,12. )
As far as EGFR expression is concerned, the results proved the same hypothesis on highest expression of EGFR as a bad prognostic marker concerning both TTP and OS.
Same was with the VEGF expression were our results proved the hypothesis on high expression VEGR as a bad prognostic marker concerning again both TTP and OS. Ideally, immediately after the operation patients could be classified in groups with higher and lower risk and consequently an adequate individual and targeted adjuvant therapy could be administered. Those groups could be formed on the basis of expression of certain molecular markers which would identify the patients with higher risk from relapse and to whom a certain form of chemotherapy would yield better results. Today, the research of significance of expression of numerous molecular markers is still under way and has not yet been implemented in routine clinical work.
CONCLUSION
We demonstrated that each of the three markers investigated, TS, EGFR and VEGF, carries prognostic significance with respect to TTP and OS for patients with Dukes C colon cancer.
Bad clinical course is specially expected if having at least the two highest expressions of investigated markers.
It is necessary to continue investigations in which we need to clearly discern groups of patients who would be predicted to derive greater benefit from the use of different adjuvant chemotherapy examining others molecular markers, as well.
Because of present difference in adjuvant chemotherapy (5FU/LV, Xeloda, FOLFOX) we sugest that patients with highest expression of at least two of those markers would be candidates for the best therapy considering expected bad clinical course.
SUMMARY PROGNOSTI^KI ZNA^AJ TIMIDILAT SINTAZE (TS), RECEPTORA EPIDERMALNOG FAKTORA RASTA (EGFR) I ENDOTELNOG VASKULARNOG FAKTORA RASTA (VEGF) NA TOK BOLESTI KOD PACIJENATA SA C STADIJUMOM KARCINOMA KOLONA
Uvod: U na{oj studiji ispitivali smo prognosti~ki zna~aj timidilat sintaze (TS), receptora epidermalnog faktora rasta (EGFR) i endotelnog vaskularnog faktora rasta (VEGF) na tok bolesti kod pacijenata sa C stadijumom karcinoma kolona.
Pacijenti i metode : U studiju je uklju~eno 100 bolesnika (isklju~eni su bolesnici sa karcinomom rektuma). Svi bolesnici su postoperativno dobili istu adjuvantnu hemioterapiju sa 5FU/Leukovorinom po Meyo protokolu. Prema klini~kom toku bolesti pacijenti su podeljeni u dve grupe: dobru u kojoj nijedan bolesnik nije imao progresiju bolesti i lo{u u kojoj su svi bolesnici progredirali tokom petogodi{njeg pra}enja. Imunohistohemijskom metodom izvr{ena su ispitivanja ekspresije ova tri markera kod svih bolesnika.
Rezultati: Ekspresija sva tri markera je bila statisti~ki zna~ajnija u grupi sa lo{om prognozom i svi su pacijenti sa maksimalnom ekspresijom ova tri markera imali statisti~ki signifikanto kra}e vreme do progresije i kra}e ukupno pre'ivljavanje. Maksimalna ekspresija bar dva od ova tri markera imala je veoma nepovoljan uticaj na tok bolesti.
Zaklju~ak: Maksimalne ekspresije TS, EGFR iVEGF imaju nepovoljan prognosti~ki zna~aj na TTP i OS kod bolesnika sa C stadijumom karcinoma kolona.
Klju~ne re~i:karcinom kolona, prognosti~ki zna~aj 
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